-

Zillow Group, Inc. (Z, ZG) Investor Alert: Robbins LLP Notifies Shareholders of Zillow Group, Inc. That Case Survived Motion to Dismiss

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors of Zillow Group, Inc. (NASDAQ: Z, ZG) that the class action complaint filed against the Company survived defendants' motion to dismiss.

The complaint, filed on behalf of shareholders who purchased Zillow securities between February 10, 2021 and November 2, 2021, alleged that the Company, through "Zillow Offers," overextended itself with excess inventory. Specifically, Zillow first announced the suspension of new contracts through 2021, citing "a backlog in renovations and operational capacity restraints." Then, Zillow announced it would wind down Zillow Offers because "the unpredictability in forecasting home prices far exceeds what we anticipated and continuing to scale Zillow Offers would result in too much earnings and balance-sheet volatility." As a result, Zillow incurred significant financial loss, and had to reduce its workforce by 25%.

On December 7, 2022, Judge Thomas S. Zilly denied defendants' motion to dismiss, with the exception of the allegations set forth in paragraph 192, which he dismissed with leave to amend. As a result, the lawsuit against Zillow will continue.

What Now: If you own shares of Zillow Group, Inc. (Z, ZG) you have an opportunity to help protect the Company and its shareholders from the damage the Company will incur in having to defend itself in the class action.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Zillow Group, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:Z

Release Summary
On December 7, 2022, Judge Thomas S. Zilly denied defendants' motion to dismiss. As a result, the lawsuit against Zillow will continue.
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom